ADVR Pursues New AIDS Drug in Expanded R&D Facility
otcnn.com
By Jack Burney
Published by OTCNN.com
09/11/2000 10:33 AM EST
At work in its new expanded research facility in Yonkers, NY, researchers of Advanced Viral Research Corporation (OTCBB: ADVR) are striving to perfect “Product R,” a new drug for AIDS therapy on which the company is banking.
Shalom Hirschman, MD, CEO said recently in a Wall Street Transcript interview that the company hopes it will be able to reach the marketplace by sometime next year. Product R, he said, is a new type of a non-toxic immunomodulator drug for the treatment of AIDS and other diseases.
He also said that ADVR’s lead drug, a peptide nucleic acid type drug, represents a new chemistry and pharmacology that could offer new types of therapies for many different diseases.
Hirschman emphasized that ADVR is a new company and hoped that the investment community would be able to separate it totally from its past.
The company believes that it has solved many important scientific problems relating to both the chemistry, pharmacology, molecular biology of its drug, and now is ready to bring the drug to market. This would be done through the FDA, submitting applications based on good science.
ADVR believes that Product R has a long pipeline, but initially, the company will only target several major diseases.
Hirschman said that ADVR already has advanced basic scientific and clinical data on the treatment of infection of the human immunodeficiency virus, that is, the treatment of AIDS. The company hopes to make its immunomodulator (Product R) one of the anchor drugs for the treatment of all patients with AIDS. ADVR thinks that there may be tremendous advantages to using this type of immunomodulator in combination with the drug that directly affects viral replication, which are the standard cocktail drugs used now. |
